{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:06:00Z","timestamp":1790618760064,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lacrimal gland adenoid cystic carcinoma (LGACC) has historically been associated with a poor prognosis even with localized disease, with a survival of 56% at 5 years. In 1988, we treated the first patient with neoadjuvant intra-arterial cytoreductive chemotherapy (IACC). Since then, we have used this protocol as the standard approach. We aim to analyze the outcomes of patients with LGACC treated with the protocol and compare them to a population-based cohort to assess if IACC can improve survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We prospectively assessed all non-metastatic patients with LGACC treated with IACC at a single institution between 1988 and 2021. For a comparison group, we identified all non-metastatic patients with LGACC treated with excision from the Surveillance, Epidemiology, and End Results (SEER) registry. We calculated disease-specific survival using the Kaplan-Meier and Cox proportional-hazards modeling methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-five non-metastatic patients with LGACC treated with IACC were identified at a single institution, and 64 patients with non-metastatic LGACC treated with excision were identified in the SEER database. The 5- and 10-year disease-specific survival rates for patients treated with IACC were 84% (95%CI 71-97) and 76% (95%CI 60-92), respectively. While the 5- and 10-year disease-specific survival rates for the population-based cohort were 72% (95%CI 62-82) and 46% (95%CI 32-60). The survival analysis favored IACC, with a 60% lower risk of death (HR: 0.4; 95%CI 0.2-0.9).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IACC improves disease-specific survival in comparison to a population-based cohort treated with excision. Additional patients treated with IACC at multiple institutions are required to provide further external validity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad346","type":"journal-article","created":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T10:25:12Z","timestamp":1703499912000},"page":"263-269","source":"Crossref","is-referenced-by-count":13,"title":["Neoadjuvant Intra-arterial Cytoreductive Chemotherapy Improves Outcomes in Lacrimal Gland Adenoid Cystic Carcinoma"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9681-0515","authenticated-orcid":false,"given":"Philippos Apolinario","family":"Costa","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Oncology, Yale University , New Haven, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Tse","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine , Miami, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Benedetto","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine , Miami, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"2024030500071941500_CIT0001","first-page":"3945","article-title":"A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the Surveillance, Epidemiology, and End Results registry","volume-title":"Cancer.","author":"Li","year":"2012"},{"key":"2024030500071941500_CIT0002","first-page":"620","article-title":"Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials","volume-title":"Head Neck.","author":"Dillon","year":"2016"},{"key":"2024030500071941500_CIT0003","first-page":"143","article-title":"Intra-arterial chemotherapy for lacrimal gland adenoid cystic carcinoma","volume-title":"Int Ophthalmol Clin.","author":"Zhang","year":"2017"},{"key":"2024030500071941500_CIT0004","first-page":"1211","article-title":"Adenoid cystic carcinomas of the salivary gland, lacrimal gland, and breast are morphologically and genetically similar but have distinct microRNA expression profiles","volume-title":"Mod Pathol.","author":"Andreasen","year":"2018"},{"key":"2024030500071941500_CIT0005","first-page":"1311","article-title":"Adenoid cystic carcinoma of the lacrimal gland: rare lethal cured","volume-title":"Ophthalmology.","author":"Bradley","year":"2013"},{"key":"2024030500071941500_CIT0006","first-page":"1313","article-title":"Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma","volume-title":"Ophthalmology.","author":"Tse","year":"2013"},{"key":"2024030500071941500_CIT0007","first-page":"99","article-title":"Lacrimal gland tumors: a clinicopathological analysis of 160 cases","volume-title":"Int Ophthalmol Clin.","author":"Ni","year":"1982"},{"key":"2024030500071941500_CIT0008","first-page":"315","article-title":"Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland","volume-title":"Arch Ophthalmol.","author":"Meldrum","year":"1998"},{"key":"2024030500071941500_CIT0009","first-page":"BIO240","article-title":"Whole exome sequencing of lacrimal gland adenoid cystic carcinoma","volume-title":"Invest Ophthalmol Vis Sci.","author":"Sant","year":"2017"},{"key":"2024030500071941500_CIT0010","first-page":"239","article-title":"Neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma: a long-term follow-up study of a trimodal strategy","volume-title":"Am J Ophthalmol.","author":"Tse","year":"2022"},{"key":"2024030500071941500_CIT0011","first-page":"e17","article-title":"Disease recurrence after intraarterial chemotherapy in 2 patients with adenoid cystic carcinoma of lacrimal gland","volume-title":"Can J Ophthalmol.","author":"Fellman","year":"2013"},{"key":"2024030500071941500_CIT0012","first-page":"44","article-title":"Clinical analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma","volume-title":"Am J Ophthalmol.","author":"Tse","year":"2006"},{"key":"2024030500071941500_CIT0013","first-page":"274","article-title":"Histopathologic observations of eyes in exenterated orbits after neoadjuvant intra-arterial cytoreductive chemotherapy for adenoid cystic carcinoma of the lacrimal gland","volume-title":"Ophthalmic Plast Reconstr Surg.","author":"Liao","year":"2020"},{"key":"2024030500071941500_CIT0014","first-page":"1268","article-title":"Changes in the 7th edition of the AJCC TNM classification and recommendations for pathologic analysis of lacrimal gland tumors","volume-title":"Arch Pathol Lab Med.","author":"Rootman","year":"2009"},{"key":"2024030500071941500_CIT0015","first-page":"128","article-title":"A clinicopathologic study of primary adenoid cystic carcinoma of the lacrimal gland","volume-title":"Ophthalmology.","author":"Lee","year":"1985"},{"key":"2024030500071941500_CIT0016","first-page":"22","article-title":"Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland","volume-title":"Ophthalmic Plast Reconstr Surg.","author":"Esmaeli","year":"2004"},{"key":"2024030500071941500_CIT0017","first-page":"768","article-title":"Prognostic factors for local recurrence and survival and impact of local treatments on survival in lacrimal gland carcinoma","volume-title":"Br J Ophthalmol.","author":"Ford","year":"2021"},{"key":"2024030500071941500_CIT0018","first-page":"1120","article-title":"Multicentre clinicopathological study of adenoid cystic carcinoma: a report of 296 cases","volume-title":"Cancer Med.","author":"Huang","year":"2021"},{"key":"2024030500071941500_CIT0019","first-page":"68","article-title":"Recurred adenoid cystic carcinoma of lacrimal gland with aggressive local invasion to the maxillary bone marrow without increased uptake in PET-CT","volume-title":"Korean J Ophthalmol.","author":"Choi","year":"2015"},{"key":"2024030500071941500_CIT0020","first-page":"84","article-title":"Long-term outcomes of globe-preserving surgery with proton beam radiation for adenoid cystic carcinoma of lacrimal gland","volume-title":"Am J Ophthalmol.","author":"Wolkow","year":"2019"},{"key":"2024030500071941500_CIT0021","first-page":"74","article-title":"Long-term outcomes of eye-sparing surgery for adenoid cystic carcinoma of lacrimal gland","volume-title":"Ophthalmic Plast Reconstr Surg.","author":"Han","year":"2018"},{"key":"2024030500071941500_CIT0022","first-page":"344","article-title":"Survival outcomes of eye-sparing surgery for adenoid cystic carcinoma of lacrimal gland","volume-title":"Jpn J Ophthalmol.","author":"Hung","year":"2019"},{"key":"2024030500071941500_CIT0023","first-page":"401","article-title":"Primary malignant neoplasms of the lacrimal gland","volume-title":"Br J Ophthalmol.","author":"Wright","year":"1992"},{"key":"2024030500071941500_CIT0024","first-page":"54","article-title":"Microdissection genotyping analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma","volume-title":"Am J Ophthalmol.","author":"Tse","year":"2006"},{"key":"2024030500071941500_CIT0025","first-page":"19","article-title":"Neoadjuvant intra-arterial chemotherapy in patients with primary lacrimal adenoid cystic carcinoma","volume-title":"Cancer Imaging.","author":"Jang","year":"2014"},{"key":"2024030500071941500_CIT0026","first-page":"216","article-title":"Limitations and biases of the Surveillance, Epidemiology, and End Results database","volume-title":"Curr Probl Cancer.","author":"Park","year":"2012"},{"key":"2024030500071941500_CIT0027","first-page":"1073","article-title":"Using large diabetes databases for research","volume-title":"J Diabetes Sci Technol.","author":"Wild","year":"2016"},{"key":"2024030500071941500_CIT0028","first-page":"2926","article-title":"The opportunities and shortcomings of using big data and national databases for sarcoma research","volume-title":"Cancer.","author":"Lyu","year":"2019"},{"key":"2024030500071941500_CIT0029","first-page":"244","article-title":"The molecular landscape of recurrent and metastatic head and neck cancers: insights from a precision oncology sequencing platform","volume-title":"JAMA Oncol.","author":"Morris","year":"2017"},{"key":"2024030500071941500_CIT0030","first-page":"147","article-title":"MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma","volume-title":"Oral Oncol.","author":"Jiang","year":"2019"},{"key":"2024030500071941500_CIT0031","first-page":"1529","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume-title":"J Clin Oncol.","author":"Tchekmedyian","year":"2019"},{"key":"2024030500071941500_CIT0032","first-page":"1356","article-title":"Clinically integrated molecular diagnostics in adenoid cystic carcinoma","volume-title":"Oncologist.","author":"Thierauf","year":"2019"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/3\/263\/56831372\/oyad346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/3\/263\/56831372\/oyad346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T19:07:28Z","timestamp":1709579248000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/3\/263\/7560290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,1,16]]},"published-print":{"date-parts":[[2024,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad346","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2024,1,16]]}}}